RED TERAV - Investigadores

Investigadores

Universidad de Navarra (CIMA). Pamplona.

Terapia Génica

Desarrollos Tecnológicos y Terapéuticos

Investigadores
Publicaciones

Cristian Smerdou Picazo

Investigador principal

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Gloria Gonalez Aseguinolaza

Investigador principal

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Puri Fortes Alonso

Investigador principal

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Rafael Aldabe Arregui

Investigador principal

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Ruben Hernandez Alcoceba

Investigador principal

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Carmen Unzu Ezquerro

Investigador colaborador

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Marta Alonso Roldan

Investigador colaborador

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Martin Bilbao Arribas

Investigador colaborador

Grupo de Investigación: Universidad de Navarra (CIMA). Pamplona.

Beloki U., Salaberry L., Ortuño-Moya C., Molina A., Smerdou C.. COVID-19 mRNA vaccines are effective at stopping a nosy virus. Molecular Therapy Nucleic Acids. 11 March 2025. DOI: 10.1016/j.omtn.2025.102458.

Impacto: 6.5. Cuartil: Q1

Pearson A.D., Mueller S., Filbin M.G., Grill J., Hawkins C., Jones C., Donoghue M., Drezner N., Weiner S., Russo M., Dun M.D., Allen J.E., Alonso M., Benaim E., Buenger V., de Rojas T., Desserich K., Fox E., Friend J., Glade Bender J., Hargrave D., Jensen M., Kholmanskikh O., Kieran M.W., Knoderer H., Koschmann C., Lesa G., Ligas F., Lipsman N., Ludwinski D., Marshall L., McDonough J., McNicholl A.G., Mirsky D., Monje M., Nysom K., Pappo A., Rosenfield A., Scobie N., Slaughter J., Smith M., Souweidane M., Straathof K., Ward L., Weigel B., Zamoryakhin D., Karres D., Vassal G.. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer. 25 February 2025. DOI: 10.1016/j.ejca.2025.115230.

Impacto: 7.6. Cuartil: Q1

Córdoba K.M., Jericó D., Jiang L., Collantes M., Alegre M., García-Ruiz L., Manzanilla O., Sampedro A., Herranz J.M., Insausti I., Martinez De La Cuesta A., Urigo F., Alcaide P., Morán M., Martín M.A., Lanciego J.L., Lefebvre T., Gouya L., Quincoces G., Unzu C., Hervas-Stubbs S., Falcón-Pérez J.M., Alegre E., Aldaz A., Fernández-Seara M.A., Peñuelas I., Berraondo P., Martini P.G.V., Avila M.A., Fontanellas A.. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates. Gut. 17 January 2025. DOI: 10.1136/gutjnl-2024-332619.

Impacto: 23.0. Cuartil: Q1 (1er decil)

Silva-Pilipich N., Beloki U., Apaolaza P., Igea A., Salaberry L., Prats-Mari L., Rovira E., Ondiviela M., Gorraiz M., Lasarte J.J., Vanrell L., Smerdou C.. Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity. Molecular Therapy. 8 January 2025. DOI: 10.1016/j.ymthe.2024.11.027.

Impacto: 12.1. Cuartil: Q1 (1er decil)

McKeown W., Hermans C., Unzu C., Kay M.A., Peyvandi F., Smith P., Miesbach W., Pierce G.F., Khair K., Valentino L.A., Pipe S.W., Pillai M., Jones M., Delwart V., Sindhurakar A., Gutstein D.E., Kessler C.M.. Operationalising a Haemophilia Gene Editing Lexicon for Practical Use. Haemophilia. 2025. DOI: 10.1111/hae.15155.

Impacto: 3.0. Cuartil: Q2

Vitanza N.A., Ronsley R., Choe M., Seidel K., Huang W., Rawlings-Rhea S.D., Beam M., Steinmetzer L., Wilson A.L., Brown C., Beebe A., Lindgren C., Gustafson J.A., Wein A., Holtzclaw S., Hoeppner C., Goldstein H.E., Browd S.R., Hauptman J.S., Lee A., Ojemann J.G., Crotty E.E., Leary S.E.S., Perez F.A., Wright J.N., Alonso M.M., Dun M.D., Foster J.B., Hurst D., Kong A., Thomsen A., Orentas R.J., Albert C.M., Pinto N., Annesley C., Gardner R.A., Ho O., Pattabhi S., Gust J., Wendler J.P., Park J.R., Jensen M.C.. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nature Medicine. 2025. DOI: 10.1038/s41591-024-03451-3.

Impacto: 58.7. Cuartil: Q1 (1er decil)

Covo-Vergara Á., Salaberry L., Silva-Pilipich N., Hervas-Stubbs S., Smerdou C.. Cell-specific delivery of CRISPR-Cas9 with pseudotyped lentiviral particles: Just change the envelope. Molecular Therapy Nucleic Acids. 10 December 2024. DOI: 10.1016/j.omtn.2024.102395.

Impacto: 6.5. Cuartil: Q1

Unzu C., Fernández-Barrena M.G.. Harnessing gene therapy for liver metabolic dysfunction: An innovative approach to MASH treatment. Molecular Therapy. 4 December 2024. DOI: 10.1016/j.ymthe.2024.11.002.

Impacto: 12.1. Cuartil: Q1 (1er decil)

Llanos-Ardaiz A., Lantero A., Neri L., Mauleón I., Ruiz de Galarreta M., Trigueros-Motos L., Weber N.D., Ferrer V., Aldabe R., Gonzalez-Aseguinolaza G.. In Vivo Selection of S/MAR Sequences to Favour AAV Episomal Maintenance in Dividing Cells. International Journal of Molecular Sciences. December 2024. DOI: 10.3390/ijms252312734.

Impacto: 4.9. Cuartil: Q1

Ortiz D.A., Peregrín N., Valencia M., Vinueza-Gavilanes R., Marín-Ordovas E., Ferrero R., Nicolás M.J., González-Aseguinolaza G., Arrasate M., Aragón T.. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model. Translational Neurodegeneration. December 2024. DOI: 10.1186/s40035-024-00441-w.

Impacto: 10.8. Cuartil: Q1 (1er decil)

Delgado-Rodriguez P., Lamanna-Rama N., Saande C., Aldabe R., Soto-Montenegro M.L., Munoz-Barrutia A.. Multiscale and multimodal evaluation of autosomal dominant polycystic kidney disease development. Communications Biology. December 2024. DOI: 10.1038/s42003-024-06868-1.

Impacto: 5.2. Cuartil: Q1

Cabanes-Creus M., Liao S.H.Y., Gale Navarro R., Knight M., Nazareth D., Lau N.S., Ly M., Zhu E., Roca-Pinilla R., Bugallo Delgado R., Vicente A.F., Baltazar G., Westhaus A., Merjane J., Crawford M., McCaughan G.W., Unzu C., González-Aseguinolaza G., Alexander I.E., Pulitano C., Lisowski L.. Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation. Nature Communications. December 2024. DOI: 10.1038/s41467-024-46194-y.

Impacto: 14.7. Cuartil: Q1 (1er decil)

Milagros S., de Erenchun P.R.R., Guembe M., Carte B., Méndez M., Uribarri A., Aldabe R.. The infectivity of AAV9 is influenced by the specific location and extent of chemically modified capsid residues. Journal of Biological Engineering. December 2024. DOI: 10.1186/s13036-024-00430-7.

Impacto: 5.7. Cuartil: Q1 (1er decil)

Garcia-Moure M., Laspidea V., Gupta S., Gillard A.G., Khatua S., Parthasarathy A., He J., Lang F.F., Fueyo J., Alonso M.M., Gomez-Manzano C.. The emerging field of viroimmunotherapy for pediatric brain tumors. Neuro-Oncology. 1 November 2024. DOI: 10.1093/neuonc/noae160.

Impacto: 16.4. Cuartil: Q1 (1er decil)

Hermans C., Valentino L.A., Thornburg C.D., Unzu C., Kay M.A., Peyvandi F., Smith P., Miesbach W., McKeown W., Pierce G.F., Khair K., Pipe S.W., Starcevic K., Pillai M., Jones M., Chiao M., Antonino I., Kessler C.. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results. Haemophilia. November 2024. DOI: 10.1111/hae.15108.

Impacto: 3.0. Cuartil: Q2

Torella L., Santana-Gonzalez N., Zabaleta N., Gonzalez Aseguinolaza G.. Gene editing in liver diseases. FEBS Letters. October 2024. DOI: 10.1002/1873-3468.14989.

Impacto: 3.0. Cuartil: Q2

Sánchez-Monteagudo A., Ripollés E., Murillo O., Domènech S., Álvarez-Sauco M., Girona E., Sastre-Bataller I., Bono A., García-Villarreal L., Tugores A., García-García F., González-Aseguinolaza G., Berenguer M., Espinós C.. Profile of plasma microRNAs as a potential biomarker of Wilson’s disease. Journal of Gastroenterology. October 2024. DOI: 10.1007/s00535-024-02135-6.

Impacto: 6.9. Cuartil: Q1

Ausejo-Mauleon I., Martinez-Velez N., Lacalle A., de la Nava D., Cebollero J., Villanueva H., Casares N., Marco-Sanz J., Laspidea V., Becher O., Patiño-García A., Labiano S., Pastor F., Alonso M.M.. Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models. JCI Insight. 24 September 2024. DOI: 10.1172/jci.insight.175257.

Impacto: 6.3. Cuartil: Q1

Drouyer M., Merjane J., Nedelkoska T., Westhaus A., Scott S., Lee S., Burke P.G.R., McMullan S., Lanciego J.L., Vicente A.F., Bugallo R., Unzu C., González-Aseguinolaza G., Gonzalez-Cordero A., Lisowski L.. Enhanced AAV transduction across preclinical CNS models: A comparative study in human brain organoids with cross-species evaluations. Molecular Therapy Nucleic Acids. 10 September 2024. DOI: 10.1016/j.omtn.2024.102264.

Impacto: 6.5. Cuartil: Q1

Silva-Pilipich N., Smerdou C.. A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers. Clinical Cancer Research. 1 September 2024. DOI: 10.1158/1078-0432.CCR-24-1126.

Impacto: 10.0. Cuartil: Q1

Nussbaumer G., Benesch M., Grabovska Y., Mackay A., Castel D., Grill J., Alonso M.M., Antonelli M., Bailey S., Baugh J.N., Biassoni V., Blattner-Johnson M., Broniscer A., Carai A., Colafati G.S., Colditz N., Corbacioglu S., Crampsie S., Entz-Werle N., Eyrich M., Friker L.L., Frühwald M.C., Garrè M.L., Gerber N.U., Giangaspero F., Gil-Da-Costa M.J., Graf N., Hargrave D., Hauser P., Herrlinger U., Hoffmann M., Hulleman E., Izquierdo E., Jacobs S., Karremann M., Kattamis A., Kebudi R., Kortmann R.D., Kwiecien R., Massimino M., Mastronuzzi A., Miele E., Morana G., Noack C.M., Pentikainen V., Perwein T., Pfister S.M., Pietsch T., Roka K., Rossi S., Rutkowski S., Schiavello E., Seidel C., Štěrba J., Sturm D., Sumerauer D., Tacke A., Temelso S., Valentini C., van Vuurden D., Varlet P., Veldhuijzen van Zanten S.E.M., Vinci M., von Bueren A.O., Warmuth-Metz M., Wesseling P., Wiese M., Wolff J.E.A., Zamecnik J., La Madrid A.M., Bison B., Gielen G.H., Jones D.T.W., Jones C., Kramm C.M.. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecul profile. Neuro-Oncology. 1 September 2024. DOI: 10.1093/neuonc/noae080.

Impacto: 16.4. Cuartil: Q1 (1er decil)

Bunuales M., Garduno A., Chillon M., Bosch A., Gonzalez-Aparicio M., Espelosin M., Garcia-Gomara M., Rico A.J., Garcia-Osta A., Cuadrado-Tejedor M., Lanciego J.L., Hernandez-Alcoceba R.. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles. Gene Therapy. September 2024. DOI: 10.1038/s41434-024-00466-w.

Impacto: 4.6. Cuartil: Q1

De La Nava D., Ausejo-Mauleon I., Laspidea V., Gonzalez-Huarriz M., Lacalle A., Casares N., Zalacain M., Marrodan L., García-Moure M., Ochoa M.C., Tallon-Cobos A.C., Hernandez-Osuna R., Marco-Sanz J., Dhandapani L., Hervás-Corpión I., Becher O.J., Nazarian J., Mueller S., Phoenix T.N., Van Der Lugt J., Hernaez M., Guruceaga E., Koschmann C., Venneti S., Allen J.E., Dun M.D., Fueyo J., Gomez-Manzano C., Gallego Perez-Larraya J., Patiño-García A., Labiano S., Alonso M.M.. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro-Oncology. 1 August 2024. DOI: 10.1093/neuonc/noae066.

Impacto: 16.4. Cuartil: Q1 (1er decil)

Juknevičienė M., Balnytė I., Valančiūtė A., Alonso M.M., Preikšaitis A., Sužiedėlis K., Stakišaitis D.. Differential Impact of Valproic Acid on SLC5A8, SLC12A2, SLC12A5, CDH1, and CDH2 Expression in Adult Glioblastoma Cells. Biomedicines. July 2024. DOI: 10.3390/biomedicines12071416.

Impacto: 3.9. Cuartil: Q1

Vazaios K., Stavrakaki Ε., Vogelezang L.B., Ju J., Waranecki P., Metselaar D.S., Meel M.H., Kemp V., van den Hoogen B.G., Hoeben R.C., Chiocca E.A., Goins W.F., Stubbs A., Li Y., Alonso M.M., Calkoen F.G., Hulleman E., van der Lugt J., Lamfers M.L.M.. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles. Molecular Therapy Oncology. 20 June 2024. DOI: 10.1016/j.omton.2024.200804.

Rubio-Pérez L., Frago S., Compte M., Navarro R., Harwood S.L., Lázaro-Gorines R., Gómez-Rosel M., Hangiu O., Silva-Pilipich N., Vanrell L., Smerdou C., Álvarez-Vallina L.. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity. Antibodies. June 2024. DOI: 10.3390/antib13020034.

Camps G., Maestro S., Torella L., Herrero D., Usai C., Bilbao-Arribas M., Aldaz A., Olagüe C., Vales A., Suárez-Amarán L., Aldabe R., Gonzalez-Aseguinolaza G.. Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice. PLoS Pathogens. May 2024. DOI: 10.1371/journal.ppat.1011749.

Impacto: 5.5. Cuartil: Q1 (1er decil)

Rodríguez-Hernández M.Á., Baena-Bustos M., Carneros D., Zurita-Palomo C., Muñoz-Pinillos P., Millán J., Padillo F.J., Smerdou C., von Kobbe C., Rose-John S., Bustos M.. Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy. eBioMedicine. May 2024. DOI: 10.1016/j.ebiom.2024.105132.

Impacto: 9.7. Cuartil: Q1 (1er decil)

Lyon G.J., Longo J., Garcia A., Inusa F., Marchi E., Shi D., Dörfel M., Arnesen T., Aldabe R., Lyons S., Nashat M.A., Bolton D.. Evaluating possible maternal effect lethality and genetic background effects in Naa10 knockout mice. PLoS ONE. May 2024. DOI: 10.1371/journal.pone.0301328.

Impacto: 2.9. Cuartil: Q1

Garcia-Moure M., Gillard A.G., Alonso M.M., Fueyo J., Gomez-Manzano C.. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage. Molecular Oncology. April 2024. DOI: 10.1002/1878-0261.13648.

Impacto: 5.0. Cuartil: Q1

Blanco E., Silva-Pilipich N., Bocanegra A., Chocarro L., Procopio A., Ausín K., Fernandez-Irigoyen J., Fernández L., Razquin N., Igea A., Garnica M., Echaide M., Arasanz H., Vera R., Escors D., Smerdou C., Kochan G.. Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies. British Journal of Cancer. 23 March 2024. DOI: 10.1038/s41416-023-02561-y.

Impacto: 6.4. Cuartil: Q1

Ausejo-Mauleon I., Labiano S., Alonso M.M.. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry. STAR Protocols. 15 March 2024. DOI: 10.1016/j.xpro.2023.102803.

Silva-Pilipich N., Lasarte-Cía A., Lasarte J.J., Smerdou C.. DNA electroporation in a vacuum: A “shocking” innovation for vaccines. Molecular Therapy Nucleic Acids. 12 March 2024. DOI: 10.1016/j.omtn.2023.102110.

Impacto: 6.5. Cuartil: Q1

Shin D.H., Jiang H., Gillard A.G., Kim D., Fan X., Singh S.K., Nguyen T.T., Sohoni S.S., Lopez-Rivas A.R., Parthasarathy A., Ene C.I., Gumin J., Lang F.F., Alonso M.M., Gomez-Manzano C., Fueyo J.. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Molecular Therapy. 6 March 2024. DOI: 10.1016/j.ymthe.2024.01.035.

Impacto: 12.1. Cuartil: Q1 (1er decil)

Maestro S., Gomez-Echarte N., Camps G., Usai C., Olagüe C., Vales A., Aldabe R., Gonzalez-Aseguinolaza G.. Deciphering the Role of Post-Translational Modifications and Cellular Location of Hepatitis Delta Virus (HDV) Antigens in HDV-Mediated Liver Damage in Mice. Viruses. March 2024. DOI: 10.3390/v16030379.

Impacto: 3.8. Cuartil: Q2

Silva-Pilipich N., Beloki U., Salaberry L., Smerdou C.. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines. March 2024. DOI: 10.3390/vaccines12030318.

Impacto: 5.2. Cuartil: Q1

Torella L., Klermund J., Bilbao-Arribas M., Tamayo I., Andrieux G., Chmielewski K.O., Vales A., Olagüe C., Moreno-Luqui D., Raimondi I., Abad A., Torrens-Baile J., Salido E., Huarte M., Hernaez M., Boerries M., Cathomen T., Zabaleta N., Gonzalez-Aseguinolaza G.. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Molecular Medicine. 16 January 2024. DOI: 10.1038/s44321-023-00008-8.

Impacto: 9.0. Cuartil: Q1 (1er decil)

Koschmann C., Al-Holou W.N., Alonso M.M., Anastas J., Bandopadhayay P., Barron T., Becher O., Cartaxo R., Castro M.G., Chung C., Clausen M., Dang D., Doherty R., Duchatel R., Dun M., Filbin M., Franson A., Galban S., Garcia Moure M., Garton H., Gowda P., Marques J.G., Hawkins C., Heath A., Hulleman E., Ji S., Jones C., Kilburn L., Kline C., Koldobskiy M.A., Lim D., Lowenstein P.R., Lu Q.R., Lum J., Mack S., Magge S., Marini B., Martin D., Marupudi N., Messinger D., Mody R., Morgan M., Mota M., Muraszko K., Mueller S., Natarajan S.K., Nazarian J., Niculcea M., Nuechterlein N., Okada H., Opipari V., Pai M.P., Pal S., Peterson E., Phoenix T., Prensner J.R., Pun M., Raju G.P., Reitman Z.J., Resnick A., Rogawski D., Saratsis A., Sbergio S.G., Souweidane M., Stafford J.M., Tzaridis T., Venkataraman S., Vittorio O., Wadden J., Wahl D., Wechsler-Reya R.J., Yadav V.N., Zhang X., Zhang Q., Venneti S.. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 8 January 2024. DOI: 10.1016/j.ccell.2023.11.002.

Impacto: 48.8. Cuartil: Q1 (1er decil)

Guedes J.P., Boyer J.B., Elurbide J., Carte B., Redeker V., Sago L., Meinnel T., Côrte-Real M., Giglione C., Aldabe R.. NatB Protects Procaspase-8 from UBR4-Mediated Degradation and Is Required for Full Induction of the Extrinsic Apoptosis Pathway. Molecular and Cellular Biology. 2024. DOI: 10.1080/10985549.2024.2382453.

Impacto: 3.2. Cuartil: Q2

Guisasola-Serrano A., Bilbao-Arribas M., Varela-Martínez E., Abendaño N., Pérez M., Luján L., Jugo B.M.. Identifying transcriptomic profiles in ovine spleen after repetitive vaccination. Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1386590.

Impacto: 5.7. Cuartil: Q1

Hangiu O., Navarro R., Frago S., Rubio-Pérez L., Tapia-Galisteo A., Díez-Alonso L., Gómez-Rosel M., Silva-Pilipich N., Vanrell L., Smerdou C., Howard K.A., Sanz L., Álvarez-Vallina L., Compte M.. Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation. Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1494206.

Impacto: 5.7. Cuartil: Q1

Botella-Asunción P., Rivero-Buceta E.M., Vidaurre-Agut C., Lama R., Rey-Campos M., Moreno A., Mendoza L., Mingo-Casas P., Escribano-Romero E., Gutierrez-Adan A., Saiz J.C., Smerdou C., Gonzalez G., Prosper F., Argemí J., Miguel J.S., Sanchez-Cordón P.J., Figueras A., Quesada-Gomez J.M., Novoa B., Montoya M., Martín-Acebes M.A., Pineda-Lucena A., Benlloch J.M.. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity. Biomedicine and Pharmacotherapy. 31 December 2023. DOI: 10.1016/j.biopha.2023.115882.

Impacto: 6.9. Cuartil: Q1 (1er decil)

Rovira E., Moreno B., Razquin N., Blázquez L., Hernández-Alcoceba R., Fortes P., Pastor F.. Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals. ACS Nano. 12 December 2023. DOI: 10.1021/acsnano.3c01994.

Impacto: 15.8. Cuartil: Q1 (1er decil)

Ricobaraza A., Bunuales M., Gonzalez-Aparicio M., Fadila S., Rubinstein M., Vides-Urrestarazu I., Banderas J., Sola-Sevilla N., Sanchez-Carpintero R., Lanciego J.L., Roda E., Honrubia A., Arnaiz P., Hernandez-Alcoceba R.. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome. Journal of Molecular Medicine. December 2023. DOI: 10.1007/s00109-023-02383-8.

Impacto: 4.8. Cuartil: Q1

Varela-Martínez E., Bilbao-Arribas M., Abendaño N., Asín J., Pérez M., Luján L., Jugo B.M.. Identification and characterization of miRNAs in spleens of sheep subjected to repetitive vaccination. Scientific Reports. December 2023. DOI: 10.1038/s41598-023-32603-7.

Impacto: 3.8. Cuartil: Q1

Ausejo-Mauleon I., Labiano S., de la Nava D., Laspidea V., Zalacain M., Marrodán L., García-Moure M., González-Huarriz M., Hervás-Corpión I., Dhandapani L., Vicent S., Collantes M., Peñuelas I., Becher O.J., Filbin M.G., Jiang L., Labelle J., de Biagi-Junior C.A.O., Nazarian J., Laternser S., Phoenix T.N., van der Lugt J., Kranendonk M., Hoogendijk R., Mueller S., De Andrea C., Anderson A.C., Guruceaga E., Koschmann C., Yadav V.N., Gállego Pérez-Larraya J., Patiño-García A., Pastor F., Alonso M.M.. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 13 November 2023. DOI: 10.1016/j.ccell.2023.09.001.

Impacto: 48.8. Cuartil: Q1 (1er decil)

Patiño-García A., Alonso M.M., Perez-Larraya J.G.. Promises of oncolytic viral therapy for adult and children with brain glioma. Current Opinion in Oncology. 1 November 2023. DOI: 10.1097/CCO.0000000000000995.

Impacto: 2.8. Cuartil: Q2

Venneti S., Kawakibi A.R., Ji S., Waszak S.M., Sweha S.R., Mota M., Pun M., Deogharkar A., Chung C., Tarapore R.S., Ramage S., Chi A., Wen P.Y., Arrillaga-Romany I., Batchelor T.T., Butowski N.A., Sumrall A., Shonka N., Harrison R.A., de Groot J., Mehta M., Hall M.D., Daghistani D., Cloughesy T.F., Ellingson B.M., Beccaria K., Varlet P., Kim M.M., Umemura Y., Garton H., Franson A., Schwartz J., Jain R., Kachman M., Baum H., Burant C.F., Mottl S.L., Cartaxo R.T., John V., Messinger D., Qin T., Peterson E., Sajjakulnukit P., Ravi K., Waugh A., Walling D., Ding Y., Xia Z., Schwendeman A., Hawes D., Yang F., Judkins A.R., Wahl D., Lyssiotis C.A., de la Nava D., Alonso M.M., Eze A., Spitzer J., Schmidt S.V., Duchatel R.J., Dun M.D., Cain J.E., Jiang L., Stopka S.A., Baquer G., Regan M.S., Filbin M.G., Agar N.Y.R., Zhao L., Kumar-Sinha C., Mody R., Chinnaiyan A., Kurokawa R., Pratt D., Yadav V.N., Grill J., Kline C., Mueller S., Resnick A., Nazarian J., Allen J.E., Odia Y., Gardner S.L., Koschmann C.. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discovery. 1 November 2023. DOI: 10.1158/2159-8290.CD-23-0131.

Impacto: 29.7. Cuartil: Q1 (1er decil)

Gómez-Moreno A., San Sebastian E., Moya J., Gomollón-Zueco P., Isola S., Vales Á., González-Aseguinolaza G., Unzu C., Garaigorta U.. Topoisomerase Inhibitors Increase Episomal DNA Expression by Inducing the Integration of Episomal DNA in Hepatic Cells. Pharmaceutics. October 2023. DOI: 10.3390/pharmaceutics15102459.

Impacto: 4.9. Cuartil: Q1

Costa-Verdera H., Unzu C., Valeri E., Adriouch S., Aseguinolaza G.G., Mingozzi F., Kajaste-Rudnitski A.. Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors. Human Gene Therapy. 1 September 2023. DOI: 10.1089/hum.2023.119.

Impacto: 3.9. Cuartil: Q1

Aguilar S., García-Olloqui P., Amigo-Morán L., Torán J.L., López J.A., Albericio G., Abizanda G., Herrero D., Vales Á., Rodríguez-Diaz S., Higuera M., García-Martín R., Vázquez J., Mora C., González-Aseguinolaza G., Prosper F., Pelacho B., Bernad A.. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress. Cells. September 2023. DOI: 10.3390/cells12182300.

Impacto: 5.1. Cuartil: Q2

Foster J.B., Alonso M.M., Sayour E., Davidson T.B., Persson M.L., Dun M.D., Kline C., Mueller S., Vitanza N.A., van der Lugt J.. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. Neoplasia (United States). August 2023. DOI: 10.1016/j.neo.2023.100909.

Impacto: 6.3. Cuartil: Q1

Vinueza-Gavilanes R., Bravo-González J.J., Basurco L., Boncristiani C., Fernández-Irigoyen J., Santamaría E., Marcilla I., Pérez-Mediavilla A., Luquin M.R., Vales A., González-Aseguinolaza G., Aymerich M.S., Aragón T., Arrasate M.. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models. Neurobiology of Disease. July 2023. DOI: 10.1016/j.nbd.2023.106166.

Impacto: 5.1. Cuartil: Q1

Fadila S., Beucher B., Dopeso-Reyes I.G., Mavashov A., Brusel M., Anderson K., Ismeurt C., Goldberg E.M., Ricobaraza A., Hernandez-Alcoceba R., Kremer E.J., Rubinstein M.. Viral vector–mediated expression of Na<inf>V</inf>1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome. Journal of Clinical Investigation. 15 June 2023. DOI: 10.1172/JCI159316.

Impacto: 13.3. Cuartil: Q1 (1er decil)

Ardanaz C.G., Ezkurdia A., Bejarano A., Echarte B., Smerdou C., Martisova E., Martínez-Valbuena I., Luquin M.R., Ramírez M.J., Solas M.. JNK3 Overexpression in the Entorhinal Cortex Impacts on the Hippocampus and Induces Cognitive Deficiencies and Tau Misfolding. ACS Chemical Neuroscience. 7 June 2023. DOI: 10.1021/acschemneuro.3c00092.

Impacto: 4.1. Cuartil: Q2

Sánchez-Guijo F., Avendaño-Solá C., Badimón L., Bueren J.A., Canals J.M., Delgadillo J., Delgado J., Eguizábal C., Fernández-Santos M.E., García-Olmo D., González-Aseguinolaza G., Juan M., Martín F., Mata R., Montserrat N., Pérez-Martínez A., Pérez-Simón J.A., Prósper F., Urbano-Ispizua Á., Zapata A.G., Sureda A., Moraleda J.M.. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01962-0.

Impacto: 4.5. Cuartil: Q1

Nassiri F., Patil V., Yefet L.S., Singh O., Liu J., Dang R.M.A., Yamaguchi T.N., Daras M., Cloughesy T.F., Colman H., Kumthekar P.U., Chen C.C., Aiken R., Groves M.D., Ong S.S., Ramakrishna R., Vogelbaum M.A., Khagi S., Kaley T., Melear J.M., Peereboom D.M., Rodriguez A., Yankelevich M., Nair S.G., Puduvalli V.K., Aldape K., Gao A., López-Janeiro Á., de Andrea C.E., Alonso M.M., Boutros P., Robbins J., Mason W.P., Sonabend A.M., Stupp R., Fueyo J., Gomez-Manzano C., Lang F.F., Zadeh G.. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature Medicine. June 2023. DOI: 10.1038/s41591-023-02347-y.

Impacto: 58.7. Cuartil: Q1 (1er decil)

Gállego Pérez-Larraya J., García-Moure M., Alonso M.M.. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas. Revue Neurologique. June 2023. DOI: 10.1016/j.neurol.2023.03.016.

Impacto: 2.8. Cuartil: Q2

González-Moreno L., Santamaría-Cano A., Paradela A., Martínez-Chantar M.L., Martín M., Pérez-Carreras M., García-Picazo A., Vázquez J., Calvo E., González-Aseguinolaza G., Saheki T., del Arco A., Satrústegui J., Contreras L.. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Molecular Genetics and Metabolism Reports. June 2023. DOI: 10.1016/j.ymgmr.2023.100967.

Impacto: 1.8. Cuartil: Q3

Elurbide J., Carte B., Guedes J., Aldabe R.. NatB Catalytic Subunit Depletion Disrupts DNA Replication Initiation Leading to Senescence in MEFs. International Journal of Molecular Sciences. May 2023. DOI: 10.3390/ijms24108724.

Impacto: 4.9. Cuartil: Q1

Weber N.D., Odriozola L., Ros-Gañán I., García-Porrero G., Salas D., Argemi J., Combal J.P., Kishimoto T.K., González-Aseguinolaza G.. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy. JHEP Reports. May 2023. DOI: 10.1016/j.jhepr.2023.100713.

Impacto: 9.5. Cuartil: Q1

Silva-Pilipich N., Blanco E., Lozano T., Martisova E., Igea A., Herrador-Cañete G., Ballesteros-Briones M.C., Gorraiz M., Sarrión P., González-Sapienza G., Lasarte J.J., Vanrell L., Smerdou C.. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. Cancer Letters. 1 May 2023. DOI: 10.1016/j.canlet.2023.216139.

Impacto: 9.1. Cuartil: Q1

Zabaleta N., Unzu C., Weber N.D., Gonzalez-Aseguinolaza G.. Gene therapy for liver diseases — progress and challenges. Nature Reviews Gastroenterology and Hepatology. May 2023. DOI: 10.1038/s41575-022-00729-0.

Impacto: 45.9. Cuartil: Q1 (1er decil)

Silva-Pilipich N., Covo-Vergara Á., Smerdou C.. Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors. Cancers. April 2023. DOI: 10.3390/cancers15082352.

Impacto: 4.5. Cuartil: Q1

Westhaus A., Cabanes-Creus M., Dilworth K.L., Zhu E., Salas Gómez D., Navarro R.G., Amaya A.K., Scott S., Kwiatek M., McCorkindale A.L., Hayman T.E., Frahm S., Perocheau D.P., Tran B.M., Vincan E., Wong S.L., Waters S.A., Riddiough G.E., Perini M.V., Wilson L.O.W., Baruteau J., Diecke S., González-Aseguinolaza G., Santilli G., Thrasher A.J., Alexander I.E., Lisowski L.. Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors. Human Gene Therapy. 1 April 2023. DOI: 10.1089/hum.2022.188.

Impacto: 3.9. Cuartil: Q1

Florea M., Nicolaou F., Pacouret S., Zinn E.M., Sanmiguel J., Andres-Mateos E., Unzu C., Wagers A.J., Vandenberghe L.H.. High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography. Molecular Therapy Methods and Clinical Development. 9 March 2023. DOI: 10.1016/j.omtm.2022.12.009.

Basurco L., Abellanas M.A., Ayerra L., Conde E., Vinueza-Gavilanes R., Luquin E., Vales A., Vilas A., Martin-Uriz P.S., Tamayo I., Alonso M.M., Hernaez M., Gonzalez-Aseguinolaza G., Clavero P., Mengual E., Arrasate M., Hervás-Stubbs S., Aymerich M.S.. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease. GLIA. March 2023. DOI: 10.1002/glia.24295.

Impacto: 5.4. Cuartil: Q1

Gonzalez-Aparicio M., Bunuales M., de Landazuri I.O., Prieto J., Hernandez-Alcoceba R.. Application of a split-Cre system for high-capacity adenoviral vector amplification. Biotechnology Journal. March 2023. DOI: 10.1002/biot.202200227.

Impacto: 3.2. Cuartil: Q2

Pastor-Fernández A., Bertos A.R., Sierra-Ramírez A., del Moral-Salmoral J., Merino J., de Ávila A.I., Olagüe C., Villares R., González-Aseguinolaza G., Rodríguez M.Á., Fresno M., Gironés N., Bustos M., Smerdou C., Fernandez-Marcos P.J., von Kobbe C.. Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice. Aging Cell. March 2023. DOI: 10.1111/acel.13771.

Impacto: 8.0. Cuartil: Q1 (1er decil)

Bilbao-Arribas M., Guisasola-Serrano A., Varela-Martínez E., Jugo B.M.. The sheep miRNAome: Characterization and distribution of miRNAs in 21 tissues. Gene. 30 January 2023. DOI: 10.1016/j.gene.2022.146998.

Impacto: 2.6. Cuartil: Q2

Fernandez-Montero A., Zuaznabar J., Pina-Sanchez M., Maestro S., Martin-Navarro L., Muñoz-Rodríguez N., Olagüe C., Pastrana M., Martínez-Fernández M., Camps G., Rodriguez J.A., Marchese F., Zazpe J., Pozuelo M., Del Pozo J., Quiroga J., Pineda-Lucena A., Reina G., Kolenda J., Moreno-Galarraga L., Gonzalez-Aseguinolaza G., Rua M., Smerdou C., Carmona-Torre F., Argemi J.. Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses. Frontiers in Cellular and Infection Microbiology. 25 January 2023. DOI: 10.3389/fcimb.2023.1110467.

Impacto: 4.6. Cuartil: Q1

Hervás-Corpión I., Alonso M.M.. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. International Review of Cell and Molecular Biology. January 2023. DOI: 10.1016/bs.ircmb.2023.04.001.

Silva-Pilipich N., Covo-Vergara Á., Vanrell L., Smerdou C.. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity. International Review of Cell and Molecular Biology. January 2023. DOI: 10.1016/bs.ircmb.2023.05.006.

Solas M., Vela S., Smerdou C., Martisova E., Martínez-Valbuena I., Luquin M.R., Ramírez M.J.. JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology. ACS Chemical Neuroscience. 2023. DOI: 10.1021/acschemneuro.3c00093.

Impacto: 4.1. Cuartil: Q2

Garcia-Moure M., Tallon-Cobos A.C., Alonso M.M.. DNA-damaging cancer cells to improve virotherapy. Molecular Therapy Oncolytics. 15 December 2022. DOI: 10.1016/j.omto.2022.10.002.

Impacto: 5.7. Cuartil: Q2

García M., Bonafont J., Martínez-Palacios J., Xu R., Turchiano G., Svensson S., Thrasher A.J., Larcher F., Del Rio M., Hernández-Alcoceba R., Garín M.I., Mencía Á., Murillas R.. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors. Molecular Therapy Methods and Clinical Development. 8 December 2022. DOI: 10.1016/j.omtm.2022.09.005.

Andres-Mateos E., Landegger L.D., Unzu C., Phillips J., Lin B.M., Dewyer N.A., Sanmiguel J., Nicolaou F., Valero M.D., Bourdeu K.I., Sewell W.F., Beiler R.J., McKenna M.J., Stankovic K.M., Vandenberghe L.H.. Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate. Nature Communications. December 2022. DOI: 10.1038/s41467-022-28969-3.

Impacto: 16.6. Cuartil: Q1 (1er decil)

Bazo A., Lantero A., Mauleón I., Neri L., Poms M., Häberle J., Ricobaraza A., Bénichou B., Combal J.P., Gonzalez-Aseguinolaza G., Aldabe R.. Gene Therapy in Combination with Nitrogen Scavenger Pretreatment Corrects Biochemical and Behavioral Abnormalities of Infant Citrullinemia Type 1 Mice. International Journal of Molecular Sciences. December 2022. DOI: 10.3390/ijms232314940.

Impacto: 5.6. Cuartil: Q1

Martínez-García J., Molina M., Odriozola L., Molina A., González-Aseguinolaza G., Weber N.D., Smerdou C.. A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector. Cell and Bioscience. December 2022. DOI: 10.1186/s13578-022-00803-9.

Bilbao-Arribas M., Jugo B.M.. Transcriptomic meta-analysis reveals unannotated long non-coding RNAs related to the immune response in sheep. Frontiers in Genetics. 22 November 2022. DOI: 10.3389/fgene.2022.1067350.

Impacto: 3.7. Cuartil: Q2

Zinn E., Unzu C., Schmit P.F., Turunen H.T., Zabaleta N., Sanmiguel J., Fieldsend A., Bhatt U., Diop C., Merkel E., Gurrala R., Peacker B., Rios C., Messemer K., Santos J., Estelien R., Andres-Mateos E., Wagers A.J., Tipper C., Vandenberghe L.H.. Ancestral library identifies conserved reprogrammable liver motif on AAV capsid. Cell Reports Medicine. 15 November 2022. DOI: 10.1016/j.xcrm.2022.100803.

Impacto: 14.3. Cuartil: Q1 (1er decil)

Aparicio B., Repáraz D., Ruiz M., Llopiz D., Silva L., Vercher E., Theunissen P., Tamayo I., Smerdou C., Igea A., Santisteban M., Gónzalez-Deza C., Lasarte J.J., Hervás-Stubbs S., Sarobe P.. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Frontiers in Immunology. 2 November 2022. DOI: 10.3389/fimmu.2022.985886.

Impacto: 7.3. Cuartil: Q1

Kronborg Hansen A.K., Dubik M., Marczynska J., Ojha B., Nistal-Villán E., González Aseguinolaza G., Arengoth D.S., Owens T., Khorooshi R.. Targeting Signaling Pathway Downstream of RIG-I/MAVS in the CNS Stimulates Production of Endogenous Type I IFN and Suppresses EAE. International Journal of Molecular Sciences. October 2022. DOI: 10.3390/ijms231911292.

Impacto: 5.6. Cuartil: Q1

Herrador-Cañete G., Zalacain M., Labiano S., Laspidea V., Puigdelloses M., Marrodan L., Garcia-Moure M., Gonzalez-Huarriz M., Marco-Sanz J., Ausejo-Mauleon I., de la Nava D., Hernández-Osuna R., Martínez-García J., Silva-Pilipich N., Gurucega E., Patiño-García A., Hernández-Alcoceba R., Smerdou C., Alonso M.M.. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma. Molecular Therapy Oncolytics. 15 September 2022. DOI: 10.1016/j.omto.2022.07.004.

Impacto: 5.7. Cuartil: Q2

Silva-Pilipich N., Lasarte-Cía A., Lozano T., Martín-Otal C., Lasarte J.J., Smerdou C.. Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer. Molecular Therapy Nucleic Acids. 13 September 2022. DOI: 10.1016/j.omtn.2022.07.020.

Impacto: 8.8. Cuartil: Q1

Murillo O., Collantes M., Gazquez C., Moreno D., Hernandez-Alcoceba R., Barberia M., Ecay M., Tamarit B., Douar A., Ferrer V., Combal J.P., Peñuelas I., Bénichou B., Gonzalez-Aseguinolaza G.. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease. Molecular Therapy Methods and Clinical Development. 8 September 2022. DOI: 10.1016/j.omtm.2022.06.001.

Olagüe C., Mitxelena-Iribarren O., Sierra-García J.E., Rodriguez-Merino F., Maestro S., Pérez-Lorenzo E., Guillen-Grima F., González-Aseguinolaza G., Arana S., Smerdou C.. Rapid SARS-CoV-2 disinfection on distant surfaces with UV-C: The inactivation is affected by the type of material. Journal of Photochemistry and Photobiology. September 2022. DOI: 10.1016/j.jpap.2022.100138.

Zabaleta N., Torella L., Weber N.D., Gonzalez-Aseguinolaza G.. mRNA and gene editing: Late breaking therapies in liver diseases. Hepatology. September 2022. DOI: 10.1002/hep.32441.

Impacto: 13.5. Cuartil: Q1 (1er decil)

Damanskienė E., Balnytė I., Valančiūtė A., Lesauskaitė V., Alonso M.M., Stakišaitis D.. The Comparative Experimental Study of Sodium and Magnesium Dichloroacetate Effects on Pediatric PBT24 and SF8628 Cell Glioblastoma Tumors Using a Chicken Embryo Chorioallantoic Membrane Model and on Cells In Vitro. International Journal of Molecular Sciences. September 2022. DOI: 10.3390/ijms231810455.

Impacto: 5.6. Cuartil: Q1

Persson M.L., Douglas A.M., Alvaro F., Faridi P., Larsen M.R., Alonso M.M., Vitanza N.A., Dun M.D.. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro-Oncology. 1 September 2022. DOI: 10.1093/neuonc/noac117.

Impacto: 15.9. Cuartil: Q1 (1er decil)

Nguyen T.T., Shin D.H., Sohoni S., Singh S.K., Rivera-Molina Y., Jiang H., Fan X., Gumin J., Lang F.F., Alvarez-Breckenridge C., Godoy-Vitorino F., Zhu L., Zheng W.J., Zhai L., Ladomersky E., Lauing K.L., Alonso M.M., Wainwright D.A., Gomez-Manzano C., Fueyo J.. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. Journal for ImmunoTherapy of Cancer. 28 July 2022. DOI: 10.1136/jitc-2022-004935.

Pérez-Larraya J.G., Garcia-Moure M., Labiano S., Patiño-García A., Dobbs J., Gonzalez-Huarriz M., Zalacain M., Marrodan L., Martinez-Velez N., Puigdelloses M., Laspidea V., Astigarraga I., Lopez-Ibor B., Cruz O., Lizarbe M.O., Hervas-Stubbs S., Alkorta-Aranburu G., Tamayo I., Tavira B., Hernandez-Alcoceba R., Jones C., Dharmadhikari G., Ruiz-Moreno C., Stunnenberg H., Hulleman E., van der Lugt J., Idoate M., Diez-Valle R., Vázquez I.E., Villalba M., de Andrea C., Núñez-Córdoba J.M., Ewald B., Robbins J., Fueyo J., Gomez-Manzano C., Lang F.F., Tejada S., Alonso M.M.. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. New England Journal of Medicine. 30 June 2022. DOI: 10.1056/NEJMoa2202028.

Impacto: 158.5. Cuartil: Q1 (1er decil)

Mitxelena-Iribarren O., Mondragon B., Pérez-Lorenzo E., Smerdou C., Guillen-Grima F., Sierra-Garcia J.E., Rodriguez-Merino F., Arana S.. Evaluation of the degradation of materials by exposure to germicide UV-C light through colorimetry, tensile strength and surface microstructure analyses. Materials Today Communications. June 2022. DOI: 10.1016/j.mtcomm.2022.103690.

Martínez-García J., Molina A., González-Aseguinolaza G., Weber N.D., Smerdou C.. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines. June 2022. DOI: 10.3390/biomedicines10061238.

Impacto: 4.7. Cuartil: Q1

Damanskienė E., Balnytė I., Valančiūtė A., Alonso M.M., Stakišaitis D.. Different Effects of Valproic Acid on SLC12A2, SLC12A5 and SLC5A8 Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. Biomedicines. May 2022. DOI: 10.3390/biomedicines10050968.

Impacto: 4.7. Cuartil: Q1

de la Nava D., Selvi K.M., Alonso M.M.. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Frontiers in Immunology. 13 April 2022. DOI: 10.3389/fimmu.2022.866892.

Impacto: 7.3. Cuartil: Q1

Laspidea V., Puigdelloses M., Labiano S., Marrodán L., Garcia-Moure M., Zalacain M., Gonzalez-Huarriz M., Martínez-Vélez N., Ausejo-Mauleon I., de la Nava D., Herrador-Cañete G., Marco-Sanz J., Guruceaga E., de Andrea C.E., Villalba M., Becher O., Squatrito M., Matía V., Pérez-Larraya J.G., Patiño-García A., Gupta S., Gomez-Manzano C., Fueyo J., Alonso M.M.. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight. 8 April 2022. DOI: 10.1172/jci.insight.154812.

Impacto: 8.0. Cuartil: Q1

Martinez-Velez N., Laspidea V., Zalacain M., Labiano S., García-Moure M., Puigdelloses M., Marrodan L., Gonzalez-Huarriz M., Herrador G., De la Nava D., Ausejo-Mauleon I., Fueyo J., Gomez-Manzano C., Patino-García A., Alonso M.M.. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Molecular Cancer Therapeutics. March 2022. DOI: 10.1158/1535-7163.MCT-21-0565.

Impacto: 5.7. Cuartil: Q2

Weber N.D., Martínez-García J., González-Aseguinolaza G.. Comment on “Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3”. Journal of Hepatology. March 2022. DOI: 10.1016/j.jhep.2021.09.033.

Impacto: 25.7. Cuartil: Q1 (1er decil)

Damanskienė E., Balnytė I., Valančiūtė A., Alonso M.M., Preikšaitis A., Stakišaitis D.. The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. International Journal of Molecular Sciences. February-2 2022. DOI: 10.3390/ijms23042001.

Impacto: 5.6. Cuartil: Q1